To mimic the of role of VSTM2A in antagonizing PD-L1 signaling under physiological levels, we first evaluated the protein amount of VSTM2A in human CRC and adjacent non-tumoral tissues using quantitative PCR (qPCR) and western blot analysis (Figures 5E and S3A). This evidence concerns the gene VSTM2A and colorectal carcinoma.